Tracking a key protein in spinal fluid could catch the disease early.
Tapping spinal fluid may yield early evidence of Alzheimer disease, years before clinical symptoms appear. Based on this premise, which is supported by increasing evidence, European scientists are pushing to use the test to distinguish the disease from other types of dementia and to help validate therapies.